Kivexa

Abacavir Sulfate and Lamivudine, the active ingredients in Kivexa, are nucleoside reverse transcriptase inhibitors (NRTIs) presented as oral tablets. They are used in combination therapy to suppress HIV-1 replication in adults and adolescents living with HIV infection. The fixed‑dose combination simplifies treatment regimens and improves adherence for patients.

GNH USA supplies Kivexa as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and providing the product to hospitals, pharmacies, and clinics worldwide through validated cold‑chain logistics and regulatory support.

Kivexa, a nucleoside reverse transcriptase inhibitor, is used in antiretroviral therapy for HIV-1 infection.

HIV-1 infection (adults): reduces viral load and increases CD4+ cell counts when used as part of combination antiretroviral therapy. HIV-1 infection (adolescents): provides effective viral suppression as part of a regimen approved for patients aged 12 years and older. Co‑infection with hepatitis B: lamivudine component offers activity against HBV, supporting liver health while treating HIV.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Hypersensitivity reaction: potentially life‑threatening, especially with abacavir in HLA‑B*57:01 carriers. - Severe liver injury: elevated transaminases, jaundice. - Lactic acidosis: metabolic disturbance requiring urgent care. - Stevens‑Johnson syndrome: severe skin and mucosal reaction.

Before initiating therapy, consider the following precautions.

Screen for HLA‑B*57:01 before starting abacavir: avoid in positive patients. Monitor liver function tests regularly: detect hepatotoxicity early. Assess renal function: dose adjustment may be needed in severe impairment. Educate patients about hypersensitivity signs: stop drug immediately if they occur. Pregnancy and breastfeeding: use only if benefit outweighs risk; limited data available. Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and light.

Kivexa may interact with several medicines; monitor accordingly.

Major Interactions (Avoid): - Concurrent use with didanosine: increased risk of pancreatitis. - Co‑administration with ribavirin: may increase hemolytic anemia. - Use with other NRTIs that cause mitochondrial toxicity: avoid combined toxicity. - Strong CYP3A4 inducers (e.g., rifampicin) may reduce lamivudine levels.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., lopinavir/ritonavir) may increase abacavir levels; monitor. - Nephrotoxic agents (e.g., tenofovir) require renal monitoring when combined.